The filing itself is a resale registration with zero primary proceeds, but it resets the clock for selling shareholder distributions. The stock is already heavily diluted and trading at $10.25/ADS on a tiny float. Watch for selling pressure from the insiders/noteholders listed as selling shareholders — any volume is material for a stock this size. The real catalyst to monitor is whether any of the $3.74 warrants get cash-exercised (a bet on the stock staying above $3.74), which would provide much-needed working capital.
Price Chart
Executive Summary
Akari Therapeutics filed an S-3 registration statement to register the resale of up to 5,999,999 ADSs (representing ~480 billion ordinary shares) by selling shareholders, all tied to the May 2026 private placement. The company will not receive any proceeds from the resale but could receive up to ~$16.5 million if all warrants are exercised for cash. With only $0.5 million in cash and a $18M market cap, this filing signals that the company's immediate funding pathway is the warrant exercise proceeds from existing investors, not new capital from a primary offering.
Key Facts
- Registers 5,999,999 ADSs (~480 billion ordinary shares) for resale by selling shareholders from the May 2026 private placement
- Company receives NO proceeds from resale; could receive ~$16.5M if all warrants exercised for cash
- May 2026 private placement issued ADSs at $3.74 per ADS plus accompanying warrants
- As of March 31, 2026, Akari had only $0.5 million in cash and a working capital deficit
- 145 insider warrants and a $2.7M convertible note add further overhang on a tiny $18M market cap
- Auditor's report includes a going-concern emphasis paragraph
- Company is pre-revenue with no commercial products and no near-term revenue expected
Financial Impact
Potential $16.5M gross from warrant exercise vs existing $0.5M cash; massive dilution potential relative to $18M market cap
Risk Factors
- Massive dilution overhang — ~480B ordinary shares registered vs 140B outstanding
- Cash balance of $0.5M insufficient to fund operations; going-concern risk
- 145 outstanding warrant series create persistent overhang; any warrant exercise adds shares
- No revenue, no approved products, no guarantee of clinical success for AKTX-101
- Mega-cap dominant ADC competitive landscape (Trodelvy, Enhertu, multiple Trop2 programs)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-031967 |
| Exhibit: ex4-7.htm | 0001493152-26-031967 |
| Exhibit: ex4-9.htm | 0001493152-26-031967 |
| Exhibit: ex4-8.htm | 0001493152-26-031967 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | DEF 14A | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $7.63 (+1.19%) |
Jul 14, 2026 14w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $7.63 (+43.14%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $7.63 (−46.31%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $7.63 (+26.71%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $7.63 (−65.40%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $7.63 (+57.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers